Joining us right now is Dan Skellyy. He's Morgan Stanley's wealth management managing director. And Dan, thanks for coming in today.Morning, Becky. Um, a lot of talk about how this is the worst week we've seen since August 1st, but we're still talking about 1% declines or or less for the major averages. And maybe that tells you more about where the markets have been recently.People keep thinking this is time for a pulled back. There's time for a pullback. What do you think, Becky.First off, we've blown past ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...

Ah, Thursday, September 25, 2025. Another day, another dizzying dance on Wall Street, orchestrated, it would seem, by the ever-unpredictable maestro, Donald J. Trump. As the Dow Jones Industrial Average (DJI) dipped 0.3% (or a more precise 171.50 points to 46,121.28), the S&P 500 (SPX) slid 0.6% (to 6,637.97), and the Nasdaq Composite (IXIC) sank a notable 0.9% (to 22,497.86), one might wonder if the markets were simply reacting to an unexpected drop in jobless claims or the Federal Reserve’s rate-cut uncer ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

新闻稿核心观点 - 新闻稿旨在推广Haggerston BioHealth投资研究小组的每周通讯 该通讯专注于追踪生物技术、制药和医疗保健行业的股票动态、关键趋势和估值驱动因素 [1] 投资研究服务内容 - 服务面向生物技术投资领域的新手和经验丰富的投资者 提供需关注的市场催化剂以及买入和卖出评级 [1] - 服务内容涵盖所有大型制药公司的产品销售数据和预测、财务预测、综合财务报表、贴现现金流分析以及逐市场分析 [1] - 服务由一位拥有超过5年生物技术、医疗保健和制药行业研究经验的顾问主导 该顾问已汇编超过1,000家公司的详细报告 [1]

公司核心观点 - 辉瑞公司被列为亿万富翁持有的十大最佳医药股之一 在全球生物制药领域处于领先地位 [1] 疫苗研发进展 - 2025年9月 公司与BioNTech报告了针对LP81变种的新版COMIRNATY新冠疫苗的积极三期数据 该疫苗在65岁以上及18-64岁高危成人中诱导了至少四倍的中和抗体增长 并保持了良好的安全性 [2] - 新版疫苗对新兴SARS-CoV-2亚系显示出强大的保护作用 已提交美国FDA审评 以支持在即将到来的流感季节为易感人群持续接种 [2] 肿瘤学管线进展 - 公司在肿瘤学领域取得显著成功 PADCEV联合KEYTRUDA方案改善了膀胱癌患者的生存率 [3] - XTANDI联合亮丙瑞林显著惠及高危转移性前列腺癌患者 这些进展凸显了公司在扩大关键癌症治疗方案方面的努力 [3] 战略与财务表现 - 公司战略目标是在2025年底前实现45亿美元的成本削减 并将节省的资金再投资于研发和创新疗法 [4] - 近期与中国三生制药等公司达成的许可协议 扩大了针对多种肿瘤类型的实验性肿瘤疗法的可及性 [4] - 公司财务表现保持强劲 其COVID-19疫苗、Paxlovid以及肿瘤学和血液学领域的业务增长提供了支撑 [4]

活动背景 - 活动由Sanford C Bernstein & Co LLC研究部门举办 分析师Courtney Breen主持[1] - Royalty Pharma公司代表参与活动并进行演讲[1] - 活动形式包括公司展示幻灯片和问答环节[2] 公司定位 - Royalty Pharma在市场中处于独特地位 业务横跨生物科技公司至大型制药公司等合作伙伴[1] 活动安排 - 活动首先由Marshall进行幻灯片演示介绍公司概况[2] - 演示结束后将进入问答环节[2] - 参与者可通过Pigeonhole应用程序提前提交问题以便整合到问答环节中[2]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?It has been a good day for companies involved in peptide drug design and development. News broke this morning that Metsera and its portfolio of glucagon like peptide 1 receptor agonist ("GLP-1 RA") drugs is set to ...

公司背景 - 内容由经验丰富的新闻记者团队独立制作 团队拥有数十年宝贵专业知识和经验[2][4] - 新闻团队覆盖全球主要金融和投资中心 在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有办事处和演播室[2] - 专家团队专注于中小型市值市场 同时为投资者提供蓝筹股、大宗商品和更广泛投资领域的最新信息[3] 内容覆盖范围 - 提供快速、可获取、信息丰富且可操作的商业和金融新闻内容 面向全球投资受众[2] - 市场报道范围包括但不限于生物技术和制药、采矿和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[3] - 内容类型能够激发和吸引活跃的私人投资者[3] 技术应用 - 采用自动化和软件工具 包括生成式人工智能技术来辅助和增强工作流程[4][5] - 所有发布内容均经过人工编辑和创作 符合内容生产和搜索引擎优化的最佳实践标准[5] - 公司始终秉持前瞻性视角并积极采用新技术[4]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...